Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Immunohistochemical evaluation of inflammatory and proliferative markers in adjacent normal thyroid tissue in patients undergoing total thyroidectomy: results of a preliminary study

Authors: Guglielmo Ardito, Luca Revelli, Alma Boninsegna, Alessandro Sgambato, Francesca Moschella, Maria Cristina Marzola, Erica Giustozzi, Nicola Avenia, Mauro Castelli, Domenico Rubello

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

Total thyroidectomy is the treatment of choice in the majority of thyroid malignancies, preventing the risk of reoperative surgery due to recurrences. In order to assess the usefulness of such an approach, expression levels of inflammatory and proliferative markers were evaluated immunohistochemically in non-lesional adjacent thyroid tissues from a group of patients who underwent total thyroidectomy for different thyroid diseases.

Methods

Nineteen consecutive patients treated by total thyroidectomy for different thyroid diseases entered the study. IL-6Rb gp130 component of the IL-6 cytokine family members receptor complexes, STAT3 cytokine signalling transduction and transcription activation factor, p53 as tumour suppressor and CK19 cytokeratin as proliferation marker were analyzed in non-lesional thyroid tissues.

Results

Gp 130 expression was detected in all tissue samples with a scattered distribution while STAT3 and p53 positivity was observed in 17 out of 19 patients with a prevailing cytoplasmic localization. Cytokeratin 19 positivity was found in patients with papillary carcinoma, in one case of follicular adenoma, 3 multinodular goiters and one Basedow disease.

Conclusion

Based on the results of this preliminary study, it may be concluded that the presence of a persisting cytokine-mediated activation associated with cytoplasmic localization of p53 is frequently observed in different thyroid diseases. Such a process seems to occur in the thyroid gland as a whole. Moreover, STAT3 activation as well as mutant p53 are risk factors for the development of neoplastic diseases. Total thyroidectomy may be supported as an adequate therapeutic approach for all the patients in whom overexpression of cytokine-dependent markers is detected.
Appendix
Available only for authorised users
Literature
1.
go back to reference Friguglietti CU, Lin CS, Kulcsar MA: Total thyroidectomy for benign thyroid diseases. Laryngoscope. 2003, 113: 1820-6. 10.1097/00005537-200310000-00030.CrossRef Friguglietti CU, Lin CS, Kulcsar MA: Total thyroidectomy for benign thyroid diseases. Laryngoscope. 2003, 113: 1820-6. 10.1097/00005537-200310000-00030.CrossRef
2.
go back to reference Wei WZ, Morris GP, Kong YC: Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother. 2004, 53: 73-8. 10.1007/s00262-003-0444-1.CrossRef Wei WZ, Morris GP, Kong YC: Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother. 2004, 53: 73-8. 10.1007/s00262-003-0444-1.CrossRef
3.
go back to reference Muller-Newen G: The cytokine receptor gp130: faithfully promiscuous. SciSTKE. 2003, 201: PE40- Muller-Newen G: The cytokine receptor gp130: faithfully promiscuous. SciSTKE. 2003, 201: PE40-
4.
go back to reference Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003, 197: 157-68. 10.1002/jcp.10364.CrossRef Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A: STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003, 197: 157-68. 10.1002/jcp.10364.CrossRef
5.
go back to reference Lin J, Jin X, Rothman K, Lin HJ, Tang H, Burke W: Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res. 2002, 62: 376-80. Lin J, Jin X, Rothman K, Lin HJ, Tang H, Burke W: Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res. 2002, 62: 376-80.
6.
go back to reference Leu C, Wong F, Chang C, Huang S, Hu C: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogenactivated protein kinase pathways. Oncogene. 2003, 22: 7809-18. 10.1038/sj.onc.1207084.CrossRef Leu C, Wong F, Chang C, Huang S, Hu C: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogenactivated protein kinase pathways. Oncogene. 2003, 22: 7809-18. 10.1038/sj.onc.1207084.CrossRef
7.
go back to reference Lin J, Tang H, Jin X, Jia G, Hsieh JT: p53 regulates STAT3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active STAT3. Oncogene. 2002, 21: 3082-8. 10.1038/sj.onc.1205426.CrossRef Lin J, Tang H, Jin X, Jia G, Hsieh JT: p53 regulates STAT3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active STAT3. Oncogene. 2002, 21: 3082-8. 10.1038/sj.onc.1205426.CrossRef
8.
go back to reference Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzglou M, Koumenis C, Taya Y, Yoshimura A, Koromilas AE: Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev. 2004, 26: 234-9. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzglou M, Koumenis C, Taya Y, Yoshimura A, Koromilas AE: Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev. 2004, 26: 234-9.
9.
go back to reference Casey MB, Lohse CM, Lloyd RV: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for CK19, galectin-3 and HBME-1. Endocr Pathol. 2003, 14: 55-60. 10.1385/EP:14:1:55.CrossRef Casey MB, Lohse CM, Lloyd RV: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for CK19, galectin-3 and HBME-1. Endocr Pathol. 2003, 14: 55-60. 10.1385/EP:14:1:55.CrossRef
10.
go back to reference Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP: Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplastic, and malignany human prosatate. J Pathol. 2004, 202: 41-49. 10.1002/path.1476.CrossRef Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP: Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplastic, and malignany human prosatate. J Pathol. 2004, 202: 41-49. 10.1002/path.1476.CrossRef
11.
go back to reference Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AK: Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst. 1994, 86: 681-7. 10.1093/jnci/86.9.681.CrossRef Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AK: Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst. 1994, 86: 681-7. 10.1093/jnci/86.9.681.CrossRef
Metadata
Title
Immunohistochemical evaluation of inflammatory and proliferative markers in adjacent normal thyroid tissue in patients undergoing total thyroidectomy: results of a preliminary study
Authors
Guglielmo Ardito
Luca Revelli
Alma Boninsegna
Alessandro Sgambato
Francesca Moschella
Maria Cristina Marzola
Erica Giustozzi
Nicola Avenia
Mauro Castelli
Domenico Rubello
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-77

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine